Drug Trial Radar · NCT05719467
SAINT: Safe Induction of Labor Trial
Last checked: Nov 20, 2026Latest source record: Apr 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,000
Planned (sponsor's estimate)
Start
Jan 3, 2023
Primary completion
Jan 31, 2025
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Oslo University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Over the past years, the rates of labor induction have increased steadily, and at present more than one in four births occurs after induced labor in Norway. There is evidence that several groups of women benefit from labor induction, including those with preeclampsia (1), postdate pregnancy, diabetes, a large-for-gestational-age fetus, gestational diabetes, prelabor rupture of membranes at term, preterm prelabor rupture of membranes, twin pregnancy and intrahepatic cholestasis of pregnancy. At the same time, induction of labor is an independent risk factor for adverse obstetric outcomes, including cesarean section, operative vaginal delivery, chorioamnionitis, labor dystocia, prolonged labor, uterine rupture, and neonatal pH \< 7.10. A recent Norwegian nationwide clinical practice pilot evaluation demonstrated that the rate of intervention was high, and that as many as 44% of women with labor induction experienced operative delivery. Given that induction of labor is a common procedure (15 000 women per year in Norway) and increases risk of several major obstetric complications, interventions that may reduce operative births and facilitate safe deliveries are highly warranted. Bicarbonate and butylscopolamine bromide have been used in smaller studies in order to shorten labor. The medications seem to be safe with a low frequency of adverse events. The rationale of the present study is therefore to assess the efficacy of oral bicarbonate and intravenous butylscopolamine bromide on facilitating spontaneous (non-operative) delivery in pregnant female participants with induction of labor.
Conditions
- Labor Complication
- Induced; Birth
- Pregnancy Related
Interventions
Buscopan 20 MG/ML Injectable SolutionDrug
1 mL intravenously
Sodium bicarbonateDrug
4 g orally
PlaceboDrug
4g orally
Nacl 0.9%Drug
1 mL intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Spontaneous vs operative birthTime frame: Through study completion, an average of one week
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Akershus University Hospital
Lørenskog, Norway · Recruiting
Oslo University Hospital Rikshospitalet
Oslo, Norway · Recruiting
Oslo University Hospital Ullevål
Oslo, Norway · Recruiting
Stavanger University Hospital
Stavanger, Norway · Recruiting
The University Hospital of North Norway
Tromsø, Norway · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.